Story

Moderna Stock Reverses Gains, Closes 4% Lower on Report of Potential White House Vaccine Order

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20262 min read
Moderna Stock Reverses Gains, Closes 4% Lower on Report of Potential White House Vaccine Order
Text size
Background

Moderna shares (NASDAQ:MRNA) reversed course to close sharply lower on Thursday after a report suggested the White House is considering an executive order that could impact U.S. vaccination schedules. The political uncertainty overshadowed a landmark regulatory approval for the company's mRNA-based influenza vaccine.

Political Headwinds Overshadow FDA Win

Moderna's stock ended the trading session down 4.2% after initially trading higher. The sell-off was triggered by a Bloomberg report stating that President Donald Trump is contemplating an executive order concerning vaccines and autism, which could be issued as soon as next week.

According to the report, while details are not yet clear, the order could potentially lead to a reduction in vaccination schedules for children. This news introduced significant uncertainty for vaccine manufacturers, with investors viewing Moderna as particularly exposed to any changes in U.S. vaccination policy.

Key Milestones for mRNA Platform

The market's negative reaction eclipsed what was otherwise a day of significant positive news for the biotechnology company, highlighting key progress in diversifying its mRNA platform beyond COVID-19.

Sample IUX Markets – In-articleAd
  • Landmark Flu Vaccine Approval: The U.S. Food and Drug Administration (FDA) approved mFLUSIVA (mRNA-1010), the first-ever mRNA-based seasonal influenza vaccine authorized in the United States. The approval covers adults aged 50 and older and allows Moderna to begin supplying the vaccine for the 2026–2027 season.
  • Ebola Vaccine Trial: Moderna also announced the start of a Phase 1 clinical trial for mRNA-1469, a vaccine candidate for the Bundibugyo ebolavirus. The program is supported by a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), which has committed up to $50 million in funding.

Market Reaction

Thursday's price action demonstrates how sensitive vaccine-focused biotechnology stocks are to political and regulatory news. The potential for a shift in government policy was enough to outweigh a major commercial and clinical milestone for Moderna.

However, the stock did pare some of its losses in after-hours trading, gaining 1.6%. This modest recovery may indicate that some investors see the political threat as a temporary risk compared to the company's long-term fundamental progress in expanding its vaccine pipeline.

Read next

More on Stocks
Back to latest news

LATEST